Tybourne Capital Management HK Ltd. Acquires Shares of 1,399,250 Alumis Inc. $ALMS

Tybourne Capital Management HK Ltd. purchased a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,399,250 shares of the company’s stock, valued at approximately $4,198,000. Alumis comprises about 12.2% of Tybourne Capital Management HK Ltd.’s holdings, making the stock its 4th largest holding. Tybourne Capital Management HK Ltd. owned 2.57% of Alumis at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Kera Capital Partners Inc. purchased a new position in shares of Alumis during the 2nd quarter valued at $32,000. Corebridge Financial Inc. increased its stake in Alumis by 53.0% in the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock worth $65,000 after acquiring an additional 3,693 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after acquiring an additional 4,926 shares during the last quarter. Rhumbline Advisers increased its position in shares of Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Alumis during the 1st quarter valued at about $105,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALMS. Morgan Stanley reduced their price objective on Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alumis in a report on Friday. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. Wells Fargo & Company started coverage on Alumis in a research note on Friday, July 25th. They issued an “overweight” rating and a $17.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Alumis in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis has a consensus rating of “Moderate Buy” and a consensus price target of $20.17.

Alumis Price Performance

Shares of ALMS opened at $4.51 on Monday. The firm has a market capitalization of $469.31 million, a P/E ratio of -0.96 and a beta of -1.47. The business has a fifty day moving average of $4.44 and a 200 day moving average of $4.23. Alumis Inc. has a one year low of $2.76 and a one year high of $13.00.

Alumis (NASDAQ:ALMS) last released its earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $2.67 million during the quarter, compared to the consensus estimate of $1.80 million. Analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.